LT-630

Cat. No.:	HY-162378
Molecular Formula:	$C_{19}H_{17}FN_4O_3$
Molecular Weight:	368.36
Target:	HDAC
Pathway:	Cell Cycle/DNA Damage; Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	LT-630 is a HDAC6 inhibitor. LT-630 ameliorates liver injury by reducing oxidative damage[1].
IC_{50} & Target	HDAC6

In Vitro

LT-630 (2-8 nM, 3 h and 24 h) inhibits Acetaminophen (HY-66005)-induced cell damage, reduces the increased oxidative stress and apoptosis in AML-12 cells[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line:	AML-12 cells
Concentration:	2-8 nM
Incubation Time:	3 h and 24 h
Result:	Reduced the increased ratio of bax/bcl-2 and the levels of cleaved caspase3 and cyt-c.

In Vivo

LT-630 (10-40 mg/kg, i.v., before APAP) inhibits Acetaminophen-induced mice oxidative stress and hepatocyte apoptosis by eliminating ROS[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	male C57BL/6J mice (16–20 g, 6-week-old)[1]
Dosage:	10-40 mg/kg befor APAP (350 mg/kg, i.p.)
Administration:	tail vein injection
Result:	Enhanced the release of GSH, SOD and NADPH. Reduced apoptosis, the bax/bcl-2 ratio, and the levels of cleaved caspase3 and cyt-c in APAP.

REFERENCES

[1]. Zhang GD, et al. A novel HDAC6 inhibitor attenuate APAP-induced liver injury by regulating MDH1-mediated oxidative stress. Int Immunopharmacol. 2024 Mar 13;131:111861.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA